NY S01350 | 2023-2024 | General Assembly

Status

Completed Legislative Action
Spectrum: Partisan Bill (Democrat 1-0)
Status: Passed on March 24 2023 - 100% progression
Action: 2023-03-24 - SIGNED CHAP.117
Text: Latest bill text (Introduced) [HTML]

Summary

Relates to brand-name drugs with and without an AB generic equivalent; amends the effective date from January to July next succeeding the date on which it shall have become a law.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Relates to brand-name drugs with and without an AB generic equivalent; amends the effective date from January to July next succeeding the date on which it shall have become a law.

Sponsors


Roll Calls

2023-03-09 - Assembly - Assembly Floor Vote - Final Passage (Y: 138 N: 0 NV: 0 Abs: 12) [PASS]
2023-02-01 - Senate - Senate Floor Vote - Final Passage (Y: 63 N: 0 NV: 0 Abs: 0) [PASS]
2023-01-17 - Senate - Senate Rules Committee Vote (Y: 20 N: 0 NV: 0 Abs: 1) [PASS]

History

DateChamberAction
2023-03-24SenateSIGNED CHAP.117
2023-03-24SenateDELIVERED TO GOVERNOR
2023-03-09Assemblyreturned to senate
2023-03-09Assemblypassed assembly
2023-03-09Assemblyordered to third reading cal.40
2023-03-09Assemblysubstituted for a3693
2023-02-01Assemblyreferred to insurance
2023-02-01SenateDELIVERED TO ASSEMBLY
2023-02-01SenatePASSED SENATE
2023-01-17SenateORDERED TO THIRD READING CAL.118
2023-01-11SenateREFERRED TO RULES

Same As/Similar To

A03693 (Same As) 2023-03-09 - substituted by s1350

New York State Sources


Bill Comments

feedback